Tag Archive 'IRC'

Lunes 20 / mayo / 2013

The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review

Filed under: Revisiones — Mario Hernández Cueto — mayo 20th, 2013 — 11:27

The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review

Hypertension Reasearch JournalPor: Anastasia G Ptinopoulou, Maria I Pikilidou y Anastasios N Lasaridis.  Hypertension Research (2013) 36, 91–101.

Data from randomized clinical trials and epidemiological evidence identify systemic hypertension as the second most common modifiable risk factor for chronic kidney disease (CKD) progression after diabetes mellitus. CKD may progress silently over the years and early diagnosis and control of hypertension is of major importance in delaying renal function decline. Recent guidelines for the treatment of hypertension suggest the use of a variety of antihypertensive drugs in order to achieve the desired blood pressure levels. Renin–angiotensin system inhibitors have been undoubtedly studied the most and are suggested by guidelines and experts as first choice in patients with hypertension and renal injury, particularly in those with diabetes, as they have repeatedly shown to significantly reduce proteinuria. [Actualizado: 20 de mayo 2013]

Comentarios desactivados

Viernes 15 / marzo / 2013

Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT)

Filed under: Revisiones — Mario Hernández Cueto — marzo 15th, 2013 — 11:17

Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT)

Hypertension Reasearch JournalPor: Takashi Yasuda, Masayuki Endoh, Daisuke Suzuki, Asio Yoshimura, Terukuni Ideura, Kozo Tamura, Kouju Kamata, Yoshiyuki Toya, Satoshi Umemura y Kenjiro Kimura for the KVT Study Group. Hypertension Research (2013) 36, 240–246.

Suppression of the renin–angiotensin system is known to slow progression of chronic kidney disease (CKD). However, few trials have been performed with Japanese patients. This study investigated whether the angiotensin receptor blocker (ARB) valsartan would delay the progression of kidney disease more effectively than conventional treatment in Japanese hypertensive patients with advanced, predialysis CKD. In a multicenter, randomized, open-label trial, 303 patients with hypertension and CKD with serum creatinine levels greater than or equal to2.0?mg?dl-1 were assigned to receive either conventional therapy plus valsartan (valsartan add-on group) or conventional therapy without ARB (control group).  [Actualizado: 15 de marzo 2013]

Comentarios desactivados